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Myostatin, a potent negative regulator of myogenesis, is proteolytically processed by furin proteases into active mature myostatin before
secretion from myoblasts. Here, we show that mature myostatin auto-regulates its processing during myogenesis. In a cell culture model of
myogenesis, Northern blot analysis revealed no appreciable change in myostatin mRNA levels between proliferating myoblasts and
differentiated myotubes. However, Western blot analysis confirmed a relative reduction in myostatin processing and secretion by
differentiated myotubes as compared to proliferating myoblasts. Furthermore, in vivo results demonstrate a lower level of myostatin
processing during fetal muscle development when compared to postnatal adult muscle. Consequently, high levels of circulatory mature
myostatin were detected in postnatal serum, while fetal circulatory myostatin levels were undetectable. Since Furin proteases are important
for proteolytically processing members of the TGF-h superfamily, we therefore investigated the ability of myostatin to control the
transcription of furin and auto-regulate the extent of its processing. Transfection experiments indicate that mature myostatin indeed regulates
furin protease promoter activity. Based on these results, we propose a mechanism whereby myostatin negatively regulates its proteolytic
processing during fetal development, ultimately facilitating the differentiation of myoblasts by controlling both furin protease gene
expression and subsequent active concentrations of mature myostatin peptide.
D 2005 Elsevier Inc. All rights reserved.Keywords: Myostatin; Myogenesis; Processing; Secretion; FurinIntroduction
Myostatin is a secreted growth factor and a member of
TGF-h superfamily. While lack of myostatin leads to
increased muscle growth (Kambadur et al., 1997; McPher-
ron et al., 1997), systemic injection of myostatin leads to
muscle wasting (Zimmers et al., 2002) indicating that
myostatin acts as a potent negative regulator of skeletal
muscle growth. Myostatin expression is detected in embry-
onic, fetal, and postnatal myogenic cells suggesting that it
plays a role in all stages of myogenesis. It is first detected in
the myogenic precursor cells of the myotome compartment
of developing somites (McPherron et al., 1997). Myostatin0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2005.03.039
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1 Contributed equally towards manuscript.expression continues throughout myogenesis and is detected
postnatally at varying levels in different axial and paraxial
muscles (Kambadur et al., 1997; McPherron et al., 1997).
Myostatin expression has also been detected at low levels in
other mammalian tissues (Ji et al., 1998; McPherron et al.,
1997; Sharma et al., 1999).
The primary structure of myostatin contains several
features shared with all members of the TGF-h superfamily.
These features include a hydrophobic core of amino acids
near the N-terminus that functions as a secretory signal and a
putative proteolytic processing site (RSRR) in the C-terminal
half of the precursor protein (McPherron and Lee, 1996). The
proteolytic processing of myostatin is carried out by a
calcium-dependent serine protease called furin (Lee and
McPherron, 2001). Furin belongs to a family of mammalian
processing enzymes called proprotein convertases (PCs), of
which seven members have so far been identified (Thomas,283 (2005) 58 – 69
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tissue distribution (Seidah and Chretien, 1997; Steiner,
1998). In particular, furin is highly concentrated in the
trans-Golgi network (Molloy et al., 1994, 1999). Importantly,
several TGF-h superfamily precursor proteins have been
shown to be cleaved by furin, including TGF-h1 (Dubois et
al., 2001) and BMP-4 (Constam and Robertson, 1999; Cui et
al., 1998, 2001). The proteolytic processing of myostatin
results in both a N-terminal Latency Associated peptide
(LAP, also referred to as pro-peptide) and a C-terminal mature
myostatin peptide (Thomas et al., 2000). The mature
myostatin is secreted into circulation as a high molecular
weight protein in association with various interacting
proteins. Titin cap and human small glutamine-rich tetratri-
copeptide repeat-containing protein (hSGT) have been shown
to associate with intracellular forms of myostatin (Nicholas et
al., 2002; Wang et al., 2003). While follistatin, follistatin
related gene (FLRG), and growth and differentiation factor-
associated serum protein-1 (GASP-1) have been shown to
bind to the extracellular circulatory form of myostatin (Hill et
al., 2002, 2003; Lee and McPherron, 2001). Recently, it is
shown that the circulatory latency myostatin protein is
activated by the BMP-1/tolloid family of metalloproteinases
(Wolfman et al., 2003) to release the mature myostatin
peptide. The mature myostatin presumably elicits its bio-
logical function by binding to its receptor, the Activin type II
B receptor (Lee and McPherron, 2001). While the mature
myostatin can bind to the receptor, the N-terminal LAP
appears to be required for the correct folding, dimerization,
and secretion of the mature peptide (Gray and Mason, 1990).
Mechanistically, myostatin appears to function by regu-
lating myoblast cell cycle progression and differentiation.
During the active proliferation phase of myoblast growth,
myostatin negatively regulates the G1 to S phase transition of
the cell cycle through both Rb dependent and independent
pathways (Langley et al., 2004; Thomas et al., 2000). In
addition, excess myostatin also inhibits myoblast terminal
differentiation by inactivating MyoD (Langley et al., 2002).
Although the function of myostatin is well defined, the
significance of myostatin processing and secretion during
myogenesis has yet to be investigated. Thus, in this
manuscript, myostatin expression, processing, and secretion
during myogenesis is investigated. The results presented
here indicate that myostatin processing and secretion is
reduced during myogenesis. An auto-regulatory loop,
whereby myostatin self-regulates its own converting
enzyme, appears to be a possible mechanism for the
regulation of myostatin processing during development.Materials and methods
Cell culture
Comprehensive methods covering cell culture and
primary myoblast extraction are detailed previously (Tho-mas et al., 2000). Briefly, C2C12 myoblasts were grown
prior to assay in proliferation media (Dulbecco’s modified
Eagle’s medium (D-MEM; Gibco-BRL, USA) containing
10% fetal bovine serum (FBS, Gibco-BRL, USA)) on
uncoated plates, while primary bovine myoblasts were
grown in Minimum essential medium-proliferation media
(MEM, Gibco-BRL, USA) containing 10% FBS on gelatin
(Sigma, St. Louis, MO, USA) coated plates. Differentiation
was induced in the C2C12 myoblasts by culture in differ-
entiation media (D-MEM) containing 2% horse serum (HS,
Gibco-BRL, USA) for 24, 48, or 72 h and in primary bovine
myoblasts by culture in MEM-differentiation media (with
2% HS) for 24, 48, or 72 h.
Transfections and luciferase assays
For transfections, C2C12 cells were seeded at a density of
15,000 cells/cm2 in 6-well plates (Nunc, Roskilde, Den-
mark) with D-MEM media containing 10% FBS. After a 24-
h attachment period, the cells were transfected with 3 Ag
total plasmid DNA (2 Ag of P1 Furin promoter (Blanchette
et al., 2001) construct and 1 Ag of SV40-h-galactosidase (h-
gal) control vector, pCH110 (Amersham Biosciences, UK))
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s recommendations. The
cultures were then incubated in an atmosphere of 5%
CO2/37-C for a further 18 h. The media was removed and
replaced with either proliferation or differentiation media.
Cultures were incubated in 5% CO2/37-C for a further 24 h.
Media was then removed and cells rinsed twice with PBS
(pH 7.4) and lysed in 300 Al of 1 Reporter lysis buffer
(Promega, Madison, WI, USA). Lysates were collected and
vortexed for 10 s. After a quick freeze-thaw the lysates were
centrifuged at 12,000  g for 15 s, and 10 Al of the
supernatant was analyzed for luciferase reporter gene
activity (Promega) in a Turner Designs Luminometer
(Model TD-20/20). To control for variations in transfection
efficiency, the transfections were performed in triplicate,
and each experiment repeated a minimum of three times.
The individual luciferase value for each assay was
normalized against h-galactosidase expression.
Myostatin indirect immunofluorescence microscopy and
photography
C2C12 myoblasts were grown prior to immunostaining in
proliferation media and seeded on Thermonox coverslips
(Nunc) at a density of 15,000 cells/cm2 for proliferation
studies or 25,000 cells/cm2 for differentiation studies.
Following a 16-h attachment period, media was changed
to either proliferation media (for the maintenance of actively
proliferating myoblasts) or differentiation media (for the
induction of differentiation and formation of myotubes).
After 72 h of incubation, cells were rinsed once with PBS
and then fixed with 70% ethanol:formaldehyde:glacial
acetic acid (20:2:1) for 30 s, rinsed three times with PBS,
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sheep serum (NSS). Cells were incubated with the specific
primary antibody; 1:100 dilution anti-myostatin antibody
(Sharma et al., 1999) in TBS containing 1% NSS for 1 h.
Rabbit IgG (5 Ag/ml; DAKO, Copenhagen, Denmark) was
used as a negative control. Cells were washed (3  5 min)
with TBS containing 0.1% Tween 20 (TBST) and incubated
with secondary antibody; 1:150 dilution biotinylated donkey
anti-rabbit IgG (RPN1004; Amersham, UK) in TBS/1%
NSS for 30 min. Cells were washed as before and incubated
with tertiary antibody; 1:100 dilution of streptavidin–biotin
fluorescein isothiocynate complex (FITC; RPN1232; Amer-
sham, UK) in TBS/1% NSS for 30 min. Cells were again
washed. Myostatin-immunofluorescence was visualized
using an UV emission wavelength of 520 nm (U-MWIG)
filter, BH2-RFL-T3 burner; Olympus Optical Co., Ger-
many). Cell nuclei were visualized by the addition of 0.3
AM 4, 6-diamidino-2-phenylindole, dihydrochloride (DAPI,
Molecular Probes, USA) to the cells for 5 min followed by
TBST wash (3  5 min), and a UV emission wavelength of
420 nm (U-MWU2 filter, BH2-RFL-T3 burner; Olympus).
FITC and DAPI fluorescence was photographed using an
Olympus BX50 microscope (Olympus) fitted with a DAGE-
MTI DC-330 color camera (DAGE-MTI) and Scion Image
Capture software.
Detection of myostatin secreted into cell culture media
Mouse C2C12 myoblasts were seeded at the density
mentioned above in 6-well plates and cultured in either
proliferation media or induced to differentiate in differ-
entiation media for 72 h. The formation of myotubes in
differentiation media cultured cells was confirmed by light
microscopy. After washing three times with PBS, the cultured
myoblasts and myotubes were incubated with methionine-
free Proliferation or differentiation media, respectively. After
30 min, the cells were washed followed by the addition of test
media. Test media consisted of methionine-free proliferation
or differentiation media supplemented with 0.5 mCi/ml of L-
[35S]-methionine (1 mCi = 37 MBq; Amersham). Cells were
incubated in precisely 2 ml of this media for 24 h.
Conditioned media was collected for the immunoprecipita-
tion of proteins, while the cells were harvested for the
quantification of DNA content (Hoechst assay).
Immunoprecipitation of myostatin from conditioned media
The conditioned media (300 Al) was precleared prior to
myostatin immunoprecipitation by incubating with 0.3 Ag of
anti-rabbit IgG HRP conjugate (P0448; DAKO) for 30 min
at 4-C. Conditioned media was then incubated with 100 Al
of 50% Protein A-Agarose (Invitrogen), washed twice with
lysis buffer for 1 h at 4-C, centrifuged, and the supernatant
(precleared media) collected. The precleared media was then
incubated with 4 Al anti-myostatin antibody for 1 h at 4-C
incubated with 50% Protein A-Agarose (Invitrogen)(washed twice with lysis buffer) for 1 h at 4-C and centrifuged
to pellet the immunoprecipitated complexes. Pellets were
washed five times with lysis buffer. Pellets were then
resuspended in 20 Al 4  NuPAGE sample buffer (Invi-
trogen). Western blot analysis for myostatin was performed
according to the published protocol (Langley et al., 2004).
Hoechst assay for the quantification of DNA
After the removal of the conditioned media from the
cultures, cells were washed in PBS and detached from the
culture dishes by incubating with 0.25% Trypsin (Sigma) in
PBS. Cells were washed again with PBS and transferred to
eppendorf tubes with 800 Al phosphate buffered saline
EDTA (PBSE; 40 mM Na2HPO4IH2O, 10 mM NaH2-
PO4IH2O, 2 M NaCl, 2 mM EDTA, pH 7.4) incubated on
ice and sonicated twice for 15 s. In a 96-well plate (Nunc),
15 Al of each sample was added to 35 Al PBSE in triplicate.
Standards (50 Al of 0 to 20 Ag/ml DNA) were also added to
the 96-well plate (Nunc). Freshly made Hoechst buffer (250
Al of 0.5 Ag/ml Hoechst in PBSE) was added to each well,
and the plates read using microplate reader (model 3550;
BioRad, Hercules, CA, USA) at 360 nm excitation and 460
nm emission wavelengths.
Detection of circulating levels of myostatin
Bovine serum samples were obtained from fetal days 70,
90, 138, 150, 165, and 240 through to adult. 2 Al of serum
from each sample was loaded onto a 4–12% Bis–Tris pre-
cast gel (Invitrogen). Subsequent Western Blot analysis for
myostatin was performed according to the published
protocol (Langley et al., 2004).
Detection of myostatin in wild type and Myostatin null mice
One milliliter of lysis buffer (PBS, pH 7.2) with 0.05%
IGEPAL detergent (Sigma Chemical Co. St. Louis, MO,
USA) and an enzyme inhibitor (Complete, Roche Diag-
nostics NZ Ltd., Auckland, New Zealand) was added to 100
mg of muscle from each animal. Samples were homogen-
ized on ice then centrifuged at 11,000  g for 10 min.
Supernatant was recovered, mixed with Laemmli loading
buffer (Laemmli, 1970), boiled for 5 min, then stored at
20-C until analysis. The protein concentration of the
supernatant was determined using the bicinchoninic acid
assay (Sigma Chemical Co.).
Twenty micrograms of protein from each muscle sample
was loaded and separated in a 10% SDS-polyacrylamide gel
under reducing conditions then transferred to a nitro-
cellulose membrane. After transfer, membranes were stained
with Ponceau S to verify transfer of protein. Membranes
were blocked and incubated in 0.05 M Tris-buffered saline
with 0.05% Tween 20 (TBST, pH 7.6), containing 0.3%
BSA, 1% polyethylene glycol (3,350 Mw), 1% polyvinyl-
pyrrolidone (10,000 Mw). Membranes were incubated with
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anti-myostatin (1:5000, sc-6884, Santa Cruz). Twenty-four
hours later, membranes were washed in TBST then
incubated for 2 h with either HRP-conjugated goat anti-
rabbit (1:10,000, Sigma Chemical Co.) or HRP conjugated
to rabbit anti-goat (1:5000, Dako) against respective
primary antibodies then washed again in TBST. Bound
HRP activity was detected with enhanced chemilumines-
cence and then blots were exposed to XOMAT AR film
(Eastman Kodak Company, Rochester, NY).
Biological activity of circulating myostatin
The AgResearch Ruakura Animal Ethics Committee
approved all animal manipulations described in this paper.
Standard superovulation and embryo transfer techniquesFig. 1. Myostatin intracellular localization. Immunofluorescence microscopy sho
differentiated C2C12 myotubes. Myostatin immunoreactive protein was detected
negative control on differentiated C2C12 myotubes. (B), (D), (F) and (H) DAPI stai
50 AM. Panels (C) and (D) are larger inserts of panels (A) and (B) respectively.were used to generate bovine Hereford  Friesian cross-
breed fetuses as described by Kambadur et al. (1997). Cows
were slaughtered at the Ruakura abattoir when fetuses were
at gestational age 120, 210, and 260 days. Fetal blood was
collected via cardiac puncture and allowed to clot at 4-C
overnight. Serum was then separated from the clot via
centrifugation at 4200 rpm for 20 min. Serum was then
filtered through a sterile 0.22 Am membrane.
Serum was then added to test media at a concentration of
10%. This test media consisted of D-MEM media (Life
Technologies, Grand Island, NY. USA), buffered with
NaHCO3 (41.9 mmol/l, Sigma Cell Culture Ltd, St. Louis,
MO, USA) and gaseous CO2. Phenol red (7.22 nmol/l,
Sigma) was used as a pH indicator. Penicillin (1  105 IU/l)
and streptomycin (100 mg/l, Sigma) were also included in
the media.wing myostatin localization in (A) proliferating C2C12 myoblasts and (E
using anti-myostatin antibodies and FITC staining. (G) Anti-rabbit IgG
ned cell nuclei of plates (A), (C), (E), and (G) respectively. Scale bar equals)
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biological activity of the serum. C2C12 (Yaffe and Saxel,
1977) cultures were seeded at 1000 cells/well (3  103 cells/
cm2) in Nunc 96-well dishes in proliferation media. After a
24 h attachment period, media was decanted and test media
described above added back to the plates. Test samples were
randomly distributed over the plate in order to avoid
possible edge effects.
Plates wrapped in parafilm then incubated in an atmos-
phere of 37-C 5% CO2. The plate was fixed at 72 h post
media change and assayed for proliferation by the method of
Oliver et al. (1989). Briefly, growth media was decanted and
cells washed once with PBS then fixed for 30 min in 10%
formol saline. The fixed cells were then stained for 30 min
with 10 g/l methylene blue in 0.01 M borate buffer (pH 8.5).
Excess stain was then removed by four sequential washes in
borate buffer. Methylene blue was then eluted off the fixed
cells by the addition of 100 Al of 1:1 (v/v) ethanol and 0.1 M
HCL. The plates were then gently shaken for 30 s and
absorbance at 655 nm measured for each well by a
microplate photometer (BioRad model 3550 microplate
reader, BioRad, Hercules, CA, USA). Absorbance is directly
proportional to cell number in this assay.Fig. 2. Myostatin processing is regulated during myogenic differentiation.
(A) Northern blot showing myostatin mRNA levels in primary bovine
myoblasts cultured from fetal day 70 hindlimb muscle in proliferation
media (prolif.) or differentiation media for 24, 48, or 72 h. The Northern
blot was probed with a 514 bp myostatin cDNA probe. The 2.9 kb
myostatin transcript is indicated. Ethidium bromide stained formaldehyde/
agarose gel showing 28S and 18S rRNA is also included. (B) Western blot
showing the levels of precursor, LAP, and mature myostatin in primary
bovine myoblasts cultured from fetal day 70 hindlimb muscle in
proliferation media (prolif.) or differentiation media for 24, 48, or 72 h.
(C) Western blot showing the levels of LAP and mature myostatin between
muscle samples obtained from wild type (WT) and myostatin null mice
(KO). Two different antibodies were used, our in house anti myostatin
antibody (FMG) and a commercially available GDF-8 antibody from Santa
Cruz (SC).Results
Intracellular localization of myostatin
Indirect immunofluorescence microscopy was performed
on myoblasts and myotubes to investigate if there are any
qualitative changes in myostatin distribution during myo-
genesis. C2C12 cell cultures were used for immunostaining.
The immunofluorescence microscopy studies show that
myostatin protein was detected in actively proliferating
C2C12 myoblasts (Fig. 1A). Specifically, myostatin immu-
nofluorescence was mainly localized in a perinuclear
pattern, often showing the characteristic reticular morphol-
ogy seen for TGF-h1 (Fig. 1C) (Miyazono et al., 1992;
Mizoi et al., 1993; Roth-Eichhorn et al., 1998). In contrast
to actively proliferating myoblasts, myostatin immunostain-
ing in differentiated myotubes was mainly localized
throughout the cytoplasm (Fig. 1E).
Myostatin processing is regulated during differentiation
Myostatin protein is synthesized and secreted from
myoblasts, and it is shown that secreted myostatin regulates
myoblast growth and differentiation systemically (Zimmers
et al., 2002). Thus, processing and/or secretion of myostatin
play a critical role in the myogenesis. To investigate if
changes in either transcription or post transcription events
regulate active levels of myostatin during myogenesis, the
levels of myostatin mRNA and the level of myostatin
processing were examined during the differentiation of
myoblasts in a cell culture system. In this experiment,bovine primary myoblasts were grown in either proliferation
media or induced to differentiate in differentiation media for
24, 48, and 72 h before being harvested for total RNA and
protein. Northern blot analysis revealed that myostatin
mRNA (2.9 kb) was present in all of the total RNA extracts,
with no appreciable change in the levels between myoblasts
cultured in proliferation media and myoblasts undergoing
differentiation in differentiation media (Fig. 2A). In the
Western blot analysis using myostatin specific antibodies,
no precursor myostatin was observed in the myoblasts
cultured in proliferation media. In the myoblasts undergoing
differentiation, however, a relatively high level of precursor
C. McFarlane et al. / Developmental Biology 283 (2005) 58–69 63myostatin was detected (Fig. 2B). In contrast to the
precursor myostatin, the level of LAP and mature myostatin
appeared to be slightly higher in actively proliferating
myoblasts than in the differentiating myoblasts (Fig. 2B). In
addition, we have performed a Western blot with both our in
house myostatin specific antibody and a commercially
available GDF-8 antibody (sc-6884, Santa Cruz) using
muscle protein extracts from wild type and myostatin null
mice. As shown in Fig. 2C, the myostatin specific anti-
bodies fail to detect the strong 26 kDa protein band, which
is observed in the wild type controls. Therefore, this
supports our assignment of the 26 kDa band to mature
myostatin.
In addition to the bovine primary myoblasts, mouse
C2C12 myoblasts were cultured in either proliferation media
or differentiation media for 24 h, and myostatin processingFig. 3. Secretion of myostatin is regulated during myogenic differentiation. (A) W
C2C12 myoblasts cultured in proliferation media (prolif.) or differentiation media
myostatin antibodies. (B) Autoradiograph of metabolically labeled LAP and matur
C2C12 myoblasts (prolif.) or differentiated C2C12 myoblasts (diff.). Myostatin imm
and fractionated by SDS-polyacrylamide gel electrophoresis. (C) Graph showin
myoblasts for the LAP and processed forms. Myostatin secretion was measured
background and normalized to total DNA content of the cells. Bars represent the a
by t test are indicated, **P < 0.01, *P < 0.05 compared to prolif. sample.was examined by Western blot analysis. In the C2C12
myoblasts cultured in proliferation media, the majority of
myostatin protein that was detected were the 26-kDa
mature and 40-kDa LAP forms. Only a relatively low
level of precursor myostatin was detected (Fig. 3A). In
myotubes by contrast, relatively high levels of the 52-kDa
precursor myostatin are detected, while low levels of the
40-kDa LAP and no 26-kDa mature myostatin were
detected (Fig. 3A). These results suggest that there is a
change in the level of proteolytic processing of myostatin
during myogenic differentiation.
Myoblasts and myotubes secrete myostatin protein
Northern and Western blot analyses performed on
myoblast extracts indicated that, while there is no changeestern blot showing the levels of precursor, LAP, and mature myostatin in
(diff.) for 24 h. Myostatin immunoreactive protein was detected using anti-
e myostatin immunoprecipitated from the conditioned media of proliferating
unoreactive protein was immunoprecipitated using anti-myostatin antibodies
g the ratio of myostatin secretion between proliferating and differentiated
by densitometric analysis of autoradiographs in panel (A), adjusted for
verage ratio of three replicates. Statistical differences ( P values) determined
Fig. 4. Myostatin processing is regulated during development. (A) Western
Blot showing the levels of myostatin precursor and latency-associated
peptide (LAP) in M. vastus lateralis. (B) Northern blot showing myostatin
expression in M. vastus lateralis from fetal days 61, 120, 160, 210, and 260
and postnatal 1, 8, 14, and adult cattle. The Northern blot was probed with a
514 bp myostatin cDNA probe. The 2.9 kb myostatin transcript is indicated.
Ethidium bromide stained formaldehyde/agarose gel showing 28S and 18S
rRNA is also included. (C) Western blot showing the levels of myostatin
precursor and latency-associated peptide (LAP) in M. semitendinosus from
fetal days 61, 120, 160, 210, and 260 and postnatal 1, 8, and 14 cattle.
Myostatin immunoreactive protein was detected using anti-myostatin
antibodies. (D) Western Blot showing the serum levels of mature myostatin
from fetal days 70, 90, 138, 150, 165, 240 to adult. 2 Al of total serum was
loaded and analyzed for myostatin expression using specific anti-myostatin
antibodies.
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is a dramatic difference in proteolytic processing of
myostatin protein. Since proteolytic processing of the
TGF-h superfamily members must occur for secretion, it
is possible that more myostatin protein is retained in
myotubes compared to myoblasts where the majority of
myostatin is processed and presumably secreted. To inves-
tigate if the rate of myostatin secretion differs between
myoblasts and differentiated myotubes, C2C12 myoblasts or
myotubes were cultured for 72 h and myostatin protein was
immunoprecipitated from the conditioned media. To dis-
tinguish between exogenous myostatin in the media serum
(10% and 2% in proliferating and differentiated cultures,
respectively) and endogenous myostatin secreted from the
cells, the cultures were pulsed with S35-methionine for a
period of 24 h. Myostatin labeled with S35-methionine
therefore represented de novo synthesized and secreted
myostatin. A Hoechst assay was also performed on the
cultured cells to normalize the detected myostatin to DNA
content.
As can be seen in Figs. 3B and C, less mature and LAP
myostatin protein was detected, per DNA content, in the
myotube conditioned media than in the proliferating
myoblast conditioned media. This result supports the above
observations that there is greater proteolytically processing
of precursor myostatin to LAP and mature forms in
proliferating myoblasts than in differentiated tubes. Thus,
an increase in processing results in more secretion of
myostatin by the myoblasts, while unprocessed precursor
myostatin is retained intracellularly in the myotubes.
Myostatin processing is regulated during development
Previously, we have demonstrated that precursor myo-
statin protein is synthesized in myoblasts and proteolytically
processed prior to secretion as a mature form (Thomas et al.,
2000). Since mature myostatin is the active signaling
peptide, proteolytic processing plays a significant role in
the regulation of myostatin function during myogenesis.
Although it has been shown that myostatin protein is
present in myoblasts and adult muscle fibers, the pattern of
myostatin processing during myogenic development is not
yet known. Hence, Western blot analysis was performed on
protein extracts from bovine fetal day 61 hindlimb, as well
as vastus lateralis (vl.) and bovine semitendinosus (st.)
muscles collected from various time points (fetal day 120 to
postnatal day 14). Myostatin protein was detected in the
precursor (52 kDa) and LAP (40 kDa) forms in nearly all of
the bovine vl. muscle extracts (Fig. 4A). In the fetal day 61
muscle extract, a relatively high level of precursor myostatin
was observed. No LAP was detected, even with a longer
exposure of the Western blot to autoradiography film (Fig.
4A). As the fetal age increased (fetal days 120–260), a
decrease in the amount of precursor myostatin and a
corresponding increase in LAP was observed (Fig. 4A).
Postnatally, the predominant form of myostatin present wasLAP, with very little precursor myostatin being detected
(Fig. 4A). To determine the level of myostatin mRNA
expression, Northern blot analysis was performed on total
RNA extracted from the same source (Bovine hindlimb
muscle, fetal day 61 and vl. muscle, fetal day 120 to
postnatal day 14) used in the Western blot analyses. As
shown in Fig. 4B, myostatin mRNA of 2.9 kb was detected
in all of the bovine muscle samples from fetal day 61
through to postnatal day 14. At fetal days 61 and 120,
Fig. 5. Biological activity of circulating myostatin. The biological activity
of myostatin in circulating fetal blood was assessed by collecting blood
from known age bovine fetuses. This blood was then used to make serum
and the biological activity of the serum assessed by its ability to promote
the proliferation of C2C12 myoblasts in a 72 h methylene blue cell staining
proliferation assay. Absorbance at 655 nm is directly proportional to cell
number at the conclusion of the assay.
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to 260 and full-term (280/postnatal day 1), the relative
levels of myostatin mRNA were increased, peaking at the
day 260 and full-term time points. Postnatally, myostatin
mRNA levels dramatically declined, as seen by the
relatively low level of myostatin mRNA in postnatal day
8 to adult (Fig. 4B). In addition to the vl. muscle, myostatin
processing during development was also examined in M.
semitendinosus muscle. A similar overall pattern of
processing that is seen for vl. was also observed in the st.
muscle (Fig. 4C). The observed increase in myostatin
processing during gestation suggests that the extent of
myostatin processing is regulated during embryonic and
fetal bovine myogenesis.
Like other TGF-h superfamily members, proteolytic
processing of the myostatin precursor molecule results in
the formation of two distinct peptides, the LAP peptide and
the C-terminal mature peptide (McPherron et al., 1997).
Following processing, both the LAP and mature myostatin
dimer are maintained in a circulatory latent complex (Lee
and McPherron, 2001). Thus, to investigate if the extent of
myostatin processing at the site of synthesis correlated with
the amount of circulatory myostatin, we analyzed levels of
myostatin in fetal blood during development. The results
show that mature myostatin was virtually undetectable
during early embryonic and fetal growth. However, post-
natally high levels of 26 kDa mature myostatin were
detected, confirming that reduced processing indeed results
in low systemic levels of myostatin (Fig. 4D). These results,
investigating the expression of myostatin, suggest that there
is an increase in myostatin mRNA and an increase in the
proteolytic processing of myostatin during fetal develop-
ment. Postnatally, however, myostatin mRNA expression
declines but a high level of processing is still maintained.
To determine if the increase in myostatin processing
during fetal development is significant with respect to
myostatin function, we have measured the biological
activity of circulating myostatin. As shown in Fig. 5,
C2C12 cells treated with serum obtained from day 260
bovine fetuses showed a 13% decrease in proliferation when
compared to cells treated with serum obtained from earlier
gestational time points. This decrease in proliferation
coincides with the large increase in myostatin processing
seen from day 260 onwards (Fig. 4).
Mature myostatin regulates furin promoter activity
Results shown above clearly indicate that differentiation
somehow reduces processing of myostatin. Furin proteases
are responsible for proteolytically processing TGF-h super-
family members; therefore, we reasoned that the observed
reduction in the processing is perhaps due to reduced furin
expression. To prove this, we transfected the P1 furin
promoter-luciferase reporter construct into C2C12 myoblasts
and measured the subsequent reporter activity during
proliferating and differentiating conditions. Consistent withthe reduction in processing of myostatin protein, furin
promoter activity is also reduced in differentiated tubes as
compared to actively growing myoblasts (Fig. 6A). This
result indirectly suggested that furin gene expression could
be regulated by myostatin. Thus, we measured the furin
promoter-luciferase reporter activity in the presence and in
the absence of myostatin. As shown in Fig. 6B, treatment of
the P1 furin promoter with myostatin decreases the promoter
activity in a concentration-dependent manner. This result
indicates that the furin promoter is negatively regulated by
myostatin.Discussion
Previously published results have shown that myostatin
is synthesized in both myoblasts and in muscle fibers,
proteolytically processed, and secreted as a mature myo-
statin peptide (Thomas et al., 2000). However, the process-
ing and secretion during myogenesis have not been widely
investigated. In this communication, we show that the
processing and secretion of myostatin is reduced upon
differentiation or during fetal fiber formation stages. We
also show that myostatin auto-regulates the extent of
processing by regulating the gene expression of its con-
verting enzyme, furin.
Myostatin expression during development
Northern blot analysis revealed that myostatin expres-
sion is developmentally regulated (Fig. 4B). Myostatin
mRNA was abundant during early fetal development (days
61 and 160), increasing at fetal day 160. A relatively high
level of myostatin mRNA was observed in each gestational
Fig. 6. Mature myostatin regulates furin promoter activity. (A) In vitro
analysis of the furin promoter during proliferation and differentiation
conditions. The furin promoter and h-galactosidase (h-gal) expression
plasmids were transfected into C2C12 myoblasts. The cells were grown for a
further 24 h in either proliferation or differentiation media after which
luciferase and h-gal activity was measured. Results reflect relative furin
promoter luciferase activity normalized to h-gal. Bars indicate means T
standard error of three independent experiments. *P < 0.05 compared to
prolif. control. (B) In Vitro analysis of the effect of myostatin on furin
promoter activity during proliferation conditions. The furin promoter and h-
galactosidase (h-gal) expression plasmids were transfected into C2C12
myoblasts. The cells were grown for a further 24 h in proliferation media
after which luciferase and h-gal activity was measured. Results reflect
relative change in furin promoter luciferase activity with increasing
myostatin concentration (+0.5 Ag/ml, ++3 Ag/ml) as compared to the un-
treated control (). Luciferase values were normalized to h-gal and the bars
indicate means T standard error of three independent experiments. Statistical
differences ( P values) determined by t test are indicated, ***P < 0.001,
**P < 0.01 compared to un-treated control ().
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being observed in the day 260 sample. After birth, the
levels of myostatin mRNA declined dramatically and
remained low in all the postnatal days (8, 14, and adult)
observed. These results are predominantly in agreement
with other results published from this laboratory in which
myostatin expression is examined by RT-PCR in bovine
semitendinosus muscle over the same time period (Oldhamet al., 2001). In the published results, a dramatic and
transient increase in myostatin expression is also observed
at fetal day 90, which lies between the two fetal time
points, days 61 and 120, examined by Northern blot
analysis in this study. This peak expression of myostatin
coincides with the peak expression of MyoD. In addition,
we have recently showed that the bovine myostatin
promoter is a downstream target gene of MyoD (Spiller
et al., 2002). Thus, it is quite possible that the deve-
lopmental expression pattern of myostatin is predominately
regulated by MyoD.
Myostatin indirect immunofluorescence microscopy
experiments on myoblasts and myotubes confirmed that
myostatin is synthesized in muscle cells (Fig. 1). Myostatin
immunoreactive protein was detected in both proliferating
myoblasts and nascent myotubes, localized in a perinuclear
pattern (Fig. 1). In addition, myostatin was localized
throughout the cytoplasm in the myotubes (Fig. 1). These
findings are consistent with studies examining TGF-h in
several cell types, whereby TGF-h1 is localized to a
perinuclear region, sometimes showing a characteristic
reticular morphology (Miyazono et al., 1992; Mizoi et al.,
1993; Roth-Eichhorn et al., 1998). In one of these studies,
the subcellular localization of TGF-h1 was determined by
immunoelectron microscopy to be in the lumen of the rER
and perinuclear cisternae of fibroblasts, macrophages, and
endothelial cells, indicating the biosynthetic process of the
protein (Mizoi et al., 1993). In another study, immuno-
fluorescence microscopy of human erythroleukemia cells
(HEL) revealed that TGF-h co-localizes with mannosidase
II, an integral Golgi protein (Miyazono et al., 1992). Taken
together, these studies indicate that TGF-h is synthesized
and secreted via the endoplasmic reticulum and Golgi,
respectively (Miyazono et al., 1992; Mizoi et al., 1993;
Roth-Eichhorn et al., 1998). Based on these reports, it is
possible that the perinuclear localization of myostatin
reflects its synthesis and processing in the endoplasmic
reticulum and Golgi. However, co-localization studies using
Golgi-specific markers, such as mannosidase II, would be
required to determine this for certain. In addition to the
perinuclear localization of myostatin, a diffuse immuno-
fluorescence was detected in the cytoplasm of the nascent
myotubes supporting the observation that less myostatin is
secreted in myotubes. Intracellular retention has also been
observed for other members of the TGF-h superfamily,
including Activin A, TGF-h1 (Miyazono et al., 1992; Roth-
Eichhorn et al., 1998), TGF-h2 (Jakowlew et al., 1991;
Roth-Eichhorn et al., 1998), and TGF-h3 (Roth-Eichhorn et
al., 1998). Latent TGF-h binding proteins (LTBPs) have
been proposed to play a role in the cytoplasmic retention of
TGF-h1, -h2, and h3 (Oklu and Hesketh, 2000). It is
unlikely that LTBPs would regulate myostatin secretion
since yeast two hybrid and co-immunoprecipitation studies
did not detect any interaction between LTBPs and myostatin
(data not shown). However, previously published results
from our laboratory suggest that the protein Titin-Cap (T-
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to the fact that over-expression of T-cap leads to reduced
secretion of myostatin (Nicholas et al., 2002). Further
myostatin interacting proteins, including follistatin, FLRG,
and GASP-1, appear to be unlikely candidates since they
have been shown to interact with myostatin in circulation
following secretion (Hill et al., 2002, 2003; Lee and
McPherron, 2001).
Processing and secretion of myostatin during myogenic
differentiation
Changes in the extent of myostatin proteolytic processing
and secretion were observed between actively proliferating
myoblasts and differentiated myotubes (Figs. 2 and 3). In
actively proliferating mouse C2C12 and bovine primary
myoblasts, the predominating forms of myostatin detected
were the mature myostatin and/or LAP, suggesting that the
myostatin precursor protein is being proteolytically pro-
cessed. In differentiating and nascent myotubes by contrast,
myostatin was observed predominantly in the precursor
form. Consistent with the processing results, we find that
during proliferation relatively more myostatin is secreted as
compared to fully differentiated myotubes. Since the
myostatin that was detected was metabolically labeled, it
likely reflects the de novo synthesis from the cells and not
myostatin introduced by media differences. Although the
processing of myostatin is altered during myogenesis, no
appreciable change in myostatin mRNA expression was
observed in the bovine primary myoblasts. Levels of LAP
and mature myostatin were measured between muscle
tissues from wild type and myostatin null mice. Using two
different specific myostatin antibodies, we have shown that
there is a dramatic loss of the 26 kDa mature myostatin
protein band in myostatin null mice (Fig. 2C), thus
providing evidence for the validity of the protein bands
we have assigned to myostatin. However, a faint band
running at 26 kDa is observed in the myostatin null muscle
tissue, this could be attributed to antibody cross reactivity
with GDF11 as GDF11 shares a high homology with the
mature region of myostatin.
Processing and secretion of myostatin during myogenesis
Lowered levels of myostatin processing occur during
fetal muscle development when compared to postnatal adult
muscle (Fig. 4). The primary observation in the examination
of myostatin expression by Western blot analysis is the
progressive shift in myostatin expression from precursor
protein to LAP (Figs. 4A and C). At fetal day 61, most of
the myostatin detected was present in the precursor form.
Between fetal days 160 and 210, relatively more processing
resulted in reduced precursor myostatin and increased LAP.
From fetal day 260 onward, the majority of observed
myostatin was present in the LAP form, suggesting that
almost all of the synthesized myostatin is processed. Sincethe processing of TGF-h superfamily members is required
for secretion and moreover secretion occurs rapidly after
processing (Miyazono et al., 1992; Roth-Eichhorn et al.,
1998), this observation suggests that during late fetal
development more myostatin is secreted. This increase in
myostatin secretion, in conjunction with an up-regulation of
myostatin gene expression, implies that there is a large
increase in mature myostatin from day 210 in the develo-
ping fetus. This is indeed supported by Western analysis
results of fetal systemic myostatin levels (Fig. 4D). While
virtually all the secreted myostatin is undetectable during
early fetal development, during postnatal adult stages,
abundant levels of myostatin were present. Myostatin
systemic expression was not detected during days 165 and
240 despite processing occurring. This could be due to the
fact that myostatin circulatory levels during these time
points were below the limits of detection for Western blot
analysis. The dramatic increase in mature myostatin from
day 210 in the fetus may result in the production of
biologically active myostatin. To examine this, we per-
formed a well-characterized bioassay for myostatin (Thomas
et al., 2000). The results show that there is a 13% drop in
C2C12 proliferation rate in cells treated with serum obtained
from fetal day 260 cattle compared to cells treated with fetal
day 210 serum (Fig. 5). This drop in proliferation rate is
consistent with known myostatin function and interestingly
coincides with the dramatic increase in myostatin processing
observed during fetal day 260 (Fig. 4).
Low levels of circulatory myostatin during early fetal
development may allow for the differentiation of primary
and secondary waves of myoblasts to occur during myo-
genesis due to the fact that excess amounts of mature
myostatin have been shown to cause a down-regulation of
MyoD expression, resulting in the inhibition of myogenic
differentiation of C2C12 myoblasts (Langley et al., 2002).
Thus, to reduce the availability of biologically active
myostatin and facilitate the process of post-mitotic differ-
entiation, myoblasts could facilitate a reduction in process-
ing of myostatin by an auto-regulatory mechanism. For such
an auto-regulatory mechanism to be feasible, ligands
involved in the functioning of TGF-h family members
should be able to directly regulate proteolytic processing
enzymes. Furin has been shown to cleave several TGF-h
family members including bone morphogenetic protein-4
(BMP-4) and TGF-h1 (Cui et al., 1998; Dubois et al., 2001).
Previously, it has been shown that TGF-h up-regulates its
own converting enzyme Furin (Blanchette et al., 1997). In
contrast, the results presented here demonstrate that
myostatin can negatively regulate furin protease promoter
expression (Fig. 6B). Recently, it has been demonstrated
that myostatin expression peaks at the onset of primary
bovine myoblast fusion with a subsequent reduction during
differentiation (Deveaux et al., 2003). Therefore, it is quite
possible that the reduced processing of myostatin seen
during differentiation is due to down-regulation of Furin
protease activity by an increase in myostatin expression
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levels during the onset of differentiation results in lowered
furin protein expression and subsequent reduction in
myostatin processing during differentiation. This novel
mechanism of negative auto-regulation allows for timely
myogenic differentiation during development leading to the
formation of myogenic fibers.
An analysis of the Furin P1 promoter has identified
several consensus E-Box sequences (data not shown), which
could indicate the involvement of bHLH transcription
factors in the regulation of furin gene expression. MyoD
is an important bHLH transcription factor involved in
regulating myogenesis. Previously, we have shown that
myostatin can cause a down-regulation of MyoD expression
resulting in an inhibition of C2C12 myoblast differentiation
(Langley et al., 2002). Therefore, increased myostatin
expression may cause a decrease in furin promoter
activation by down-regulating MyoD expression.
Collectively our studies show that there is reduced
proteolytic processing of myostatin protein during myo-
genesis and that myostatin negatively regulates the tran-
scription of its own converting enzyme, furin. Given that
myostatin is a negative regulator of myogenesis, we
hypothesize that myostatin auto-regulates its processing,
thereby regulating the process of myoblast terminal
differentiation.Acknowledgments
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